Phio Pharmaceuticals Corp (PHIO)

$1.16 -0.01 (-0.85%)
Market Cap 12.49M
Revenue (ttm) 0.00
Net Income (ttm) -7.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 328,300
Avg Vol 4,613,162
Day's Range N/A - N/A
Shares Out 10.76M
Stochastic %K 72%
Beta 0.90
Analysts Sell
Price Target $14.00

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology
Sector: Healthcare
Phone: 508 767 3861
Address:
11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States
spikespants
spikespants Mar. 6 at 10:06 PM
$PHIO how do they beat earnings consensus by +8.7¢ (27.22%) and finish down . 01? C'mon man I realized they have no revenue, but everybody knows this.
1 · Reply
ckruel
ckruel Mar. 6 at 3:58 PM
$PHIO Strong Ph762 Clinical Data and strong cash position support, Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals, retaining the price target of $14.00.
0 · Reply
CoffeeBender
CoffeeBender Mar. 6 at 2:43 PM
$PHIO Good to see this holding as the market continues to sour.
0 · Reply
zannnn
zannnn Mar. 6 at 10:45 AM
$PHIO
0 · Reply
prm2021
prm2021 Mar. 5 at 9:46 PM
$PHIO can it reach life time high of 4 again with all these news ?
1 · Reply
RetiredOldGeezer
RetiredOldGeezer Mar. 5 at 9:17 PM
$PHIO Earnings as expected - cash is stil good. Looks positive,
0 · Reply
newsfile_corp
newsfile_corp Mar. 5 at 9:06 PM
https://nfne.ws/286264 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt
0 · Reply
DosGatos
DosGatos Mar. 5 at 7:33 PM
$PHIO
0 · Reply
DERDER
DERDER Mar. 5 at 5:35 PM
$PHIO
0 · Reply
ckruel
ckruel Mar. 5 at 3:40 PM
$PHIO
0 · Reply
Latest News on PHIO
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

Mar 5, 2026, 4:05 PM EST - 2 days ago

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Mar 5, 2026, 7:00 AM EST - 2 days ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?

Feb 12, 2026, 8:43 AM EST - 23 days ago

What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients

Feb 10, 2026, 11:12 AM EST - 25 days ago

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients

Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Feb 10, 2026, 7:00 AM EST - 25 days ago

Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

Jan 26, 2026, 8:15 AM EST - 5 weeks ago

Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Jan 20, 2026, 9:30 AM EST - 6 weeks ago

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Jan 15, 2026, 8:45 AM EST - 7 weeks ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Dec 23, 2025, 8:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Nov 25, 2025, 11:30 AM EST - 3 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 17, 2025, 8:45 AM EST - 3 months ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 4:15 PM EST - 4 months ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 10:30 AM EST - 4 months ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 7, 2025, 7:45 AM EST - 4 months ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 1:40 PM EST - 4 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Nov 3, 2025, 7:45 AM EST - 4 months ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 31, 2025, 10:15 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 18, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:15 PM EDT - 7 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 3:04 PM EDT - 8 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 12:36 PM EDT - 8 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jul 25, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 25, 2025, 7:45 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 24, 2025, 7:45 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Jun 6, 2025, 7:45 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 19, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 4:15 PM EDT - 10 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

May 7, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 9, 2025, 7:45 AM EDT - 11 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Apr 3, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 10, 2025, 7:45 AM EDT - 1 year ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Mar 5, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Feb 20, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 22, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 21, 2025, 4:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 12:45 PM EST - 1 year ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 13, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Jan 2, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 23, 2024, 1:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 12, 2024, 9:21 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Dec 10, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024, 5:47 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

spikespants
spikespants Mar. 6 at 10:06 PM
$PHIO how do they beat earnings consensus by +8.7¢ (27.22%) and finish down . 01? C'mon man I realized they have no revenue, but everybody knows this.
1 · Reply
ckruel
ckruel Mar. 6 at 3:58 PM
$PHIO Strong Ph762 Clinical Data and strong cash position support, Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals, retaining the price target of $14.00.
0 · Reply
CoffeeBender
CoffeeBender Mar. 6 at 2:43 PM
$PHIO Good to see this holding as the market continues to sour.
0 · Reply
zannnn
zannnn Mar. 6 at 10:45 AM
$PHIO
0 · Reply
prm2021
prm2021 Mar. 5 at 9:46 PM
$PHIO can it reach life time high of 4 again with all these news ?
1 · Reply
RetiredOldGeezer
RetiredOldGeezer Mar. 5 at 9:17 PM
$PHIO Earnings as expected - cash is stil good. Looks positive,
0 · Reply
newsfile_corp
newsfile_corp Mar. 5 at 9:06 PM
https://nfne.ws/286264 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt
0 · Reply
DosGatos
DosGatos Mar. 5 at 7:33 PM
$PHIO
0 · Reply
DERDER
DERDER Mar. 5 at 5:35 PM
$PHIO
0 · Reply
ckruel
ckruel Mar. 5 at 3:40 PM
$PHIO
0 · Reply
Dodo1112
Dodo1112 Mar. 5 at 2:26 PM
$PHIO Can see $1.5 soon ?
0 · Reply
PitaPierogi
PitaPierogi Mar. 5 at 12:49 PM
$PHIO buyout soon.
0 · Reply
newsfile_corp
newsfile_corp Mar. 5 at 12:02 PM
https://nfne.ws/286314 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt
0 · Reply
TheNewMochaJoe
TheNewMochaJoe Mar. 5 at 9:36 AM
$PHIO
0 · Reply
zannnn
zannnn Mar. 5 at 9:18 AM
$PHIO
0 · Reply
trader_23
trader_23 Mar. 5 at 12:17 AM
$PHIO
0 · Reply
DosGatos
DosGatos Mar. 4 at 8:53 PM
$PHIO They are warming up!!!
0 · Reply
TheNewMochaJoe
TheNewMochaJoe Mar. 4 at 8:32 PM
$PHIO Why we moving?
0 · Reply
fromtheothersid3
fromtheothersid3 Mar. 4 at 8:02 PM
$PHIO Shorts have some serious trouble soon here imho ☺️❤️
0 · Reply
DERDER
DERDER Mar. 4 at 7:50 PM
$PHIO 2nd Quarter, get ready for the run!!!
0 · Reply
audiobookprisonstories
audiobookprisonstories Mar. 4 at 3:40 PM
$PHIO bought back in
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 6:23 PM
$PHIO RSI: 47.20, MACD: -0.0121 Vol: 0.19, MA20: 1.10, MA50: 1.09 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply